Asset profile
DDO-3055
Small molecule
Evidence outlook · lead readout
NCT03976115 · Chronic Kidney Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT03976115: Participants were randomized and the study was double-blind with a placebo comparator, but the primary endpoint was adverse-event incidence rather than a disease outcome, and results have not yet been posted, so the design's promise cannot yet be confirmed by data.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.